OKYO Pharma Ltd OKYO

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2026 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Net income ——-$4.7M-$16.8M-$13.3M-$5.4M-$3.4M-$1.5M—

Balance sheet

Fiscal year FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assets ——$3.7M$1.5M$5.2M$4.3M$7.1M——
Total equity ——-$5.5M-$5.9M-$2.1M$2.9M$5.3M-$140.1K$333.2K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-036599.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • R&D
  • Total equity
  • Total current liabilities
R&D, Total equity, Total current liabilities by fiscal year, in US dollars The same figures are in the table below this chart. -10M -5M 0 5M 10M Total equity, FY2018: 333.2K Total equity, FY2019: -140.1K Total equity, FY2020: 5.3M Total equity, FY2021: 2.9M Total equity, FY2022: -2.1M Total equity, FY2023: -5.9M Total equity, FY2024: -5.5M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025 FY2026
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
R&D — — — — — — — — —
Total equity $333.2K -$140.1K $5.3M $2.9M -$2.1M -$5.9M -$5.5M — —
Total current liabilities — — — — — — — — —

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $236.38B 30.7x 10.0%
GILD GILEAD SCIENCES, INC. $187.23B 22.3x 2.4%
MRNA Moderna, Inc. $58.11B — -39.9%
RVMD Revolution Medicines, Inc. $45.01B — —
BIIB BIOGEN INC. $32.60B 25.1x 2.2%
SCNI Scinai Immunotherapeutics Ltd. $25.80B — 99.2%
NBIX NEUROCRINE BIOSCIENCES INC $15.82B 33.3x 21.4%
EXEL EXELIXIS, INC. $14.62B 21.2x 7.0%